CSL CSL Limited

Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas

As hurricane recovery efforts continue in Texas, the U.S. Department of Health and Human Services (DHHS), has requested urgent support to help displaced residents fight the onset of influenza.

Seqirus, a global leader in the prevention of influenza, announced today that it is donating 22,500 doses of influenza vaccine to the Texas Department of State Health Services, the appropriate state public health authority spearheading the deployment of the donation.

The company’s donation consists of premium influenza vaccines – a cell-based flu vaccine, manufactured in the company’s state-of-the art Holly Springs facility in North Carolina, and an adjuvanted vaccine specifically developed for people 65 and older. The donation will be used in vaccination programs for people living in local shelters.

"Our thoughts are with the thousands of people in Texas affected by the devastation caused by Hurricane Harvey, and we stand ready to help Floridians as Hurricane Irma bears down on Florida,” said Gordon Naylor, President at Seqirus. “Protecting communities from diseases is our purpose and the reason we come to work every day. During this difficult time, we are grateful for the people working tirelessly on relief efforts and glad that we can make a contribution.”

The majority of doses supplied by Seqirus were manufactured at the company’s state-of-the-art facility in Holly Springs, North Carolina. Seqirus built the facility in partnership with the U.S. government with the express goal of protecting Americans from influenza pandemics. It is the largest influenza vaccine manufacturing facility in the country and the only site to produce influenza vaccine using cell-based viral technology.

Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and, in some cases, death.1 The CDC estimates that 310,000 people in the United States were hospitalized due to influenza-related complications during the 2015-2016 influenza season.2

“Even in normal conditions, influenza is a highly contagious disease that can cause severe illness and life-threatening complications,” said Russell Basser, Chief Medical Officer and Senior Vice President of Research & Development at Seqirus. “In the aftermath of a natural disaster of this magnitude, many people find temporary housing and live in close quarters, which greatly increases the risk of infection.”

“The doses of influenza vaccine donated by Seqirus will ensure that more displaced Texans will receive preventive treatment more quickly and effectively,” added Dr. Basser.

CSL Limited, Seqirus’ parent company, is also supporting hurricane relief efforts through its other affiliates with a presence in the United States. Florida-based subsidiary CSL Plasma has made a corporate donation of $150,000 to the United Way of Greater Houston Relief Fund. Also, for every dollar donated by an employee, CSL will match the contribution in full.

For more information, visit www.seqirus-US.com.

About Seqirus

Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 20,000 people and has operations in more than 60 countries.

Seqirus was established on 31 July 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. As the second largest influenza vaccine provider in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.

Seqirus operates state-of-the-art production facilities in the US, the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries.

References

  1. CDC. “Key Facts About Influenza (Flu).” Available at: https://www.cdc.gov/flu/keyfacts.htm. Accessed July 2017.
  2. CDC. “Seasonal Influenza-Associated Hospitalizations in the United States.” Available at: https://www.cdc.gov/flu/about/qa/hospital.htm. Accessed July 2017.

Seqirus is a CSL Limited company. ASX:CSL ABN: 26 260 735 035

EN
13/09/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CSL Limited

CSL Limited: 1 director

A director at CSL Limited maiden bought 3,400 shares at 29.337USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

CSL Limited: Update to credit analysis

Our credit view of this issuer reflects a good track record and its plasma-derived therapy industry, constrained by its debt/EBITDA above the 2.75x threshold and its plasma collection costs.

CSL Limited - December 2023 (LTM): Peer Snapshot 

Compares key performance metrics against industry peers.

CSL Limited: Update to credit analysis

Our credit view of this issuer reflects a good track record and its plasma-derived therapy industry, against its debt/EBITDA above the 2.7x threshold and its plasma collection costs.

CSL Limited - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch